SCHEMBL6147663

SCHEMBL6147663

CC1(C)CCC(C)(C)c2cc(C(C=O)OCc3ccccc3)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 7/20 0.43
RXRB P28702 3/20 0.43
CYP26A1 O43174 3/20 0.43
CYP26B1 Q9NR63 2/20 0.43
CYP3A4 P08684 1/20 0.43
RARB P10826 7/20 0.40
RARG P13631 7/20 0.40
RARA P10276 6/20 0.40
PPARG P37231 1/20 0.39
RXRG P48443 2/20 0.39
HNF4A P41235 2/20 0.38
SLC1A3 P43003 2/20 0.37
SLC1A2 P43004 2/20 0.37
SLC1A1 P43005 2/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6147285 0.81 RXRA (0.47) RXRARXRBCYP26A1CYP26B1CYP3A4
SCHEMBL6148176 0.79 RARB (0.66) RXRARXRBCYP26A1CYP26B1CYP3A4
SCHEMBL6147667 0.79 RARB (0.66) RXRARXRBCYP26A1CYP26B1CYP3A4
SCHEMBL6147281 0.78 RXRA (0.44) RXRARXRBCYP26A1CYP26B1CYP3A4
SCHEMBL6148846 0.77 RXRA (0.46) RXRARXRBCYP26A1CYP26B1CYP3A4
SCHEMBL6148854 0.77 RXRA (0.46) RXRARXRBCYP26A1CYP26B1CYP3A4
SCHEMBL6145801 0.77 CYP26A1 (0.48) RXRARXRBCYP26A1CYP26B1CYP3A4
SCHEMBL8467072 0.75 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL9025351 0.75 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL6147935 0.75 RXRA (0.44) RXRARXRBCYP26A1CYP26B1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280757-B1 NEW GAMMA SELECTIVE RETINOIDS HOFFMANN LA ROCHE (CH) 2005-08-17 EP disclosed
US-6603012-B2 RAR selective retinoid agonists HOFFMANN-LA ROCHE INC. 2003-08-05 US disclosed
EP-1280757-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2003-02-05 EP disclosed
US-20020026060-A1 RAR selective retinoid agonists F.HOFFMANN-LA ROCHE AG (CH) 2002-02-28 US disclosed
WO-2001083438-A2 NEW GAMMA SELECTIVE RETINOIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026060-A1 RAR selective retinoid agonists RARA, RARG, RARB RXRA 4/4885RXRB 6/4885CYP26A1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.